Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma

Published:2023-07 Issue:1 Volume:84 Page:109-116
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Ernst Matthew S.,Navani Vishal,Wells J. Connor,Donskov Frede,Basappa Naveen,Labaki Chris,Pal Sumanta K.,Meza Luis,Wood Lori A.,Ernst D. Scott,Szabados Bernadett,McKay Rana R.,Parnis Francis,Suarez Cristina,Yuasa Takeshi,Lalani Aly-Khan,Alva Ajjai,Bjarnason Georg A.,Choueiri Toni K.,Heng Daniel Y.C.

Publisher

Elsevier BV

Subject

Urology

Reference12 articles.

1. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study;Heng;J Clin Oncol,2009

2. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study;Heng;Lancet Oncol,2013

3. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

4. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

5. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma;Choueiri;N Engl J Med,2021

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Treatment of Residual Disease After Immunotherapy-Based Combinations on Complete Response Rate of Patients With Metastatic Renal Cell Carcinomas;Clinical Genitourinary Cancer;2024-10

2. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors;Cellular Oncology;2024-09-02

3. Renal Cell Carcinoma;JAMA;2024-08-28

4. Contemporary Management of Renal Cell Carcinoma: A Review for General Practitioners in Oncology;Current Oncology;2024-08-22

5. Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database;Current Oncology;2024-08-18